Could Gilead Sciences Have an HIV Cure Waiting in the Wings?

Most of the buzz over Gilead Sciences (NASDAQ: GILD) in recent months has centered on its antiviral drug remdesivir. That's understandable, considering that the drug is currently the most promising therapy targeting COVID-19.

Gilead has also been in headlines over the past week after reports surfaced that big pharmaceutical company AstraZeneca was interested in acquiring the biotech. The possibility of a deal, though, seems to have evaporated now.

But while these are the stories that have kept Gilead at the forefront of investors' attention for now, there's another one that could be the real game-changer for the biotech in the not-too-distant future. Could Gilead Sciences have an HIV cure waiting in the wings?

Continue reading

Source Fool.com